Mangoceuticals shares fell 12.24% to $0.42 in after-hours trading Thursday after the company announced that its former wholly owned subsidiary, MangoRx IP Holdings, entered subscription agreements with two strategic investors for an aggregate $2.5 million investment. MangoRx IP has received the initial $1.75 million tranche for a 17.5% membership interest, while the remaining 7.5% stake requires a $750,000 payment by Nov. 28, 2026. The subsidiary-level transaction does not involve issuing Mangoceuticals common stock, warrants or other securities, leaving its outstanding share count unchanged. MangoRx IP owns the patent portfolio behind MGX-0024, the company's antiviral technology, including U.S. Patent No. 11,517,523 and corresponding patents granted or pending across several international markets. Mangoceuticals develops health and wellness products through its MangoRx and PeachesRx telemedicine brands. The company had a market capitalization of approximately $10.32 million, while its shares were down 78.06% over the past year and traded between $0.16 and $2.75. In regular trading Thursday, the stock rose 12.24% to close at $0.48.